Menu
Recruiting NCT06993155

A Clinical Trial Evaluating the Efficacy and Safety of Leflutrozole on Testicular Function

Phase II Interventional Semen Quality

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Leflutrozole, Dose 1, Leflutrozole, Dose 2, Leflutrozole, Dose 3, Placebo.
Who it may be relevant to
Registry conditions: Semen Quality. Basic parameters: 18 years — 49 years · Male.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Randomized, Placebo-controlled, Double-blind, Parallel-group, Dose-response Trial Evaluating the Efficacy and Safety of Leflutrozole on Testicular Function

Overview

The goal of this clinical trial is to evaluate three doses of the drug leflutrozole on improvement of semen quality in men. It will also study the safety of leflutrozole. The main questions it aims to answer are: * Does leflutrozole improve semen quality? * What medical problems do participants experience when taking leflutrozole? Researchers will compare leflutrozole to a placebo (a look-alike substance that contains no drug). Participants will: * Take leflutrozole or a placebo orally once a week for 16 weeks. * Visit the clinic every 4 weeks for checkups and tests. * Provide semen samples to measure changes in semen quality. * Have their blood tested to measure hormone levels and ensure safety. * Be monitored for any side effects.

Interventions

  • Drug Leflutrozole, Dose 1
    Leflutrozole, Dose 1 once weekly for 16 weeks
  • Drug Leflutrozole, Dose 2
    Leflutrozole, Dose 2 once weekly for 16 weeks
  • Drug Leflutrozole, Dose 3
    Leflutrozole, Dose 3 once weekly for 16 weeks
  • Drug Placebo
    Placebo once weekly for 16 weeks

Primary outcome measures

  • Change in total motile sperm count (TMSC) after 16 weeks of treatment. [Time frame: From baseline to the end of treatment at 16 weeks.]
Secondary outcome measures (12)
  • Changes in total sperm count (TSC), sperm concentration, sperm motility, normal sperm morphology, and semen volume after 16 weeks of treatment. [Time frame: From baseline to the end of treatment at 16 weeks.]
  • Percentage of participants with TMSC ≥5 million, ≥10 million, and ≥20 million after 16 weeks of treatment. [Time frame: At end of treatment at 16 weeks.]
  • Percentage of participants with a relative increase of ≥50%, ≥75% and ≥100% in TMSC after 16 weeks of treatment. [Time frame: From baseline to the end of treatment at 16 weeks.]
  • Percentage of participants with sperm DNA fragmentation index (DFI) <15%, <25% and <30% after 16 weeks of treatment. [Time frame: At end of treatment at 16 weeks.]
  • Percentage of participants with serum total testosterone levels within the range of 450-1000 ng/dL after 4, 8, 12 and 16 weeks of treatment. [Time frame: At 4 , 8, 12 and 16 weeks of treatment.]
  • Percentage of participants with serum total testosterone levels within the normal range of 300-1000 ng/dL after 4, 8, 12 and 16 weeks of treatment (for participants with baseline levels <300 ng/dL). [Time frame: At 4 , 8, 12 and 16 weeks of treatment.]
  • Changes in serum concentrations of total testosterone, free testosterone, bioavailable testosterone, SHBG, FSH, LH, estradiol, inhibin B, and total testosterone / estradiol ratio after 4, 8, 12 and 16 weeks of treatment. [Time frame: From baseline to 4 , 8, 12 and 16 weeks of treatment.]
  • Plasma concentrations of leflutrozole after 4, 8, 12 and 16 weeks of treatment. [Time frame: At 4 , 8, 12 and 16 weeks of treatment.]
  • Semen concentrations of leflutrozole after 12 weeks of treatment. [Time frame: After 12 weeks of treatment.]
  • Changes in libido based upon questionnaire after 4 and 16 weeks of treatment. [Time frame: From baseline to 4 and 16 weeks of treatment.]
  • Changes in energy based upon questionnaire after 4 and 16 weeks of treatment. [Time frame: From baseline to 4 and 16 weeks of treatment.]
  • Percentage of participants who overshoot testosterone at any time during the trial. [Time frame: At any time during the trial]

Eligibility criteria

Inclusion criteria

  • Signed informed consent form prior to any-related trial activity.
  • Adult men aged 18-49 years (both inclusive).
  • Low serum total testosterone concentration on two occasions.
  • Serum estradiol (E2) level within or above normal range at screening.
  • Serum Luteinizing Hormone level within or below normal range at screening.
  • Low total motile sperm count in two samples.
  • Semen volume ≥1.0 mL in two samples.
  • Ability to understand and comply with the requirements of the protocol.

Exclusion criteria

  • Anatomical abnormalities of the testes or malignant or benign tumors of the testes.
  • Pituitary or hypothalamic disease.
  • Prostate disease.
  • Treatment with one or more of the following prescription drugs or over-the-counter medications or supplements for 6 months prior to the screening visit:
  • Compounds with androgenic or estrogenic properties (i.e., agonist or antagonist) or that affect production of sex hormones.
  • 5-α reductase inhibitors, e.g., finasteride and dutasteride.
  • Fertility drugs, including clomiphene, FSH, hMG and hCG preparations.
  • Growth hormone.
  • Opioid-receptor antagonists, e.g., naloxone and long-acting opioids.
  • Selective α-adrenergic-receptor antagonists (alpha blockers).
  • Topical or systemic testosterone replacement therapy (TRT).
  • Anabolic steroids.
  • Inability to reliably produce the required semen samples for trial assessments due to significant erectile dysfunction, anorgasmia, or other reasons.
  • Participation in any clinical trial using clinical intervention within 3 months before the screening visit or 5 half-lives of investigational product administration, whichever is shorter.
  • Any clinically significant 12-lead ECG abnormalities at screening.
  • Known history of thromboembolic disease.
  • Grade 3 lower extremity edema.
  • Known cardiovascular disease.
  • Known history of osteoporosis or fragility fractures.
  • Known moderate or severe impairment of renal or hepatic function.
  • Untreated diagnosis of sleep apnea.
  • History of cancer within the last 5 years.
  • Known alcohol and/or drug abuse within the last 12 months prior to randomization or evidence of such abuse indicated by the laboratory results during the screening assessments.
  • Known chronic opioid use and/or misuse within the last 12 months prior to randomization.
  • Any psychiatric or medical disorder or circumstance, which in the investigator's opinion might jeopardize participant's safety or compliance with the protocol.
  • Hypersensitivity to any active ingredients or excipients in the medicinal products used in this trial.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Treatment

Study locations

United States · 4 centers
  • ReproNovo Investigational Site — North Hollywood
  • ReproNovo Investigational Site — Pomona
  • ReproNovo Investigational Site — Garden City
  • ReproNovo Investigational Site — Middleburg Heights

Identifiers

NCT: NCT06993155 · RPN-LFT01

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗